← Search & browse all drugs
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › PROTEIN KINASE INHIBITORS › Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors
erdafitinib
L01EN01
Forms & Strengths
- tablets: 0.5mg, 1mg, 2mg, 3mg, 4mg, 5mg, 6mg, 8mg, 9mg
Adult Dosing
- 8mg orally once daily, may be increased to 9mg if tolerated
Pediatric Dosing
- not established for patients under 18 years of age
Indications
- locally advanced or metastatic urothelial carcinoma with susceptible FGFR3/2 alterations
Mechanism of Action
- selective inhibitor of fibroblast growth factor receptor 1/2/3 kinases
Contraindications
- hypersensitivity to erdafitinib
Adverse Reactions
- stomatitis, fatigue, asthenia, diarrhea, decreased appetite, dry mouth, nail toxicity, constipation
Drug Interactions
- CYP2C9 and CYP3A4 inhibitors may increase erdafitinib exposure, CYP2C9 and CYP3A4 inducers may decrease erdafitinib exposure
Curated Content: Needs Vetting Before Put to Clinical Use